Eyepoint Pharmaceuticals appoints Tarek S Hassan as chief strategic science officer for wet AMD push

Eyepoint Pharmaceuticals appoints Tarek S Hassan as chief strategic science officer for wet AMD push
Eyepoint names new science officer

Eyepoint Pharmaceuticals has named Tarek S Hassan, M.D., as its new chief strategic science officer, bringing more than 35 years of ophthalmology experience to the executive team.

The appointment comes as the company prepares to release topline data from its Phase 3 clinical trial for wet age-related macular degeneration (AMD) starting this quarter. Eyepoint Pharmaceuticals expects Dr Hassan’s expertise to support its strategic efforts as it advances treatments in the ophthalmology field.

Eyepoint Pharmaceuticals recently urged early detection as wet AMD symptoms can progress rapidly, citing the relevance of its ongoing clinical trial program here. The company also took part in the Montreal ASRS annual meeting to promote collaboration and innovation in retina care earlier this year. These efforts come as Eyepoint advances its clinical development in ophthalmology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.